Avenue Therapeutics to Host Virtual Annual Meeting of Stockholders
May 29 2020 - 8:30AM
Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company
focused on the development of intravenous (“IV”) tramadol for the
U.S. market, today announced that it will host the Company’s 2020
Annual Meeting of Stockholders (“Annual Meeting”) virtually due to
public health concerns resulting from the coronavirus (COVID-19)
outbreak, and government-recommended and required limits on public
gatherings. Holding the Annual Meeting online will also protect the
health and safety of the Company’s stockholders, directors and
employees.
The Annual Meeting will begin at 10:00 a.m.
Eastern Time on Tuesday, June 16, 2020, and will be conducted in a
virtual format only. Stockholders will not be able to attend the
Annual Meeting in person; however, stockholders of record as of the
close of business on April 20, 2020 will be able to vote through
the online platform.
Investors can access the virtual Annual Meeting
and participate in the following ways:
- Visit www.virtualshareholdermeeting.com/ATXI2020 and enter the
16-digit control number included on your Important Notice Regarding
the Availability of Proxy Materials.
- Log into the meeting platform beginning at 9:45 a.m. Eastern
Time on June 16, 2020.
- Vote during the Annual Meeting by following the instructions
available on the meeting website during the Annual Meeting.
A list of stockholders entitled to vote at the
Annual Meeting will be available for examination for any purpose
germane to the Annual Meeting for ten days prior to the Annual
Meeting. You may email Avenue Therapeutics, Inc. at ir@avenuetx.com
to coordinate arrangements to view the stockholder list. The
stockholder list will also be available during the Annual Meeting
at www.virtualshareholdermeeting.com/ATXI2020.
If you encounter any technical difficulties with
the virtual meeting platform on the meeting day, a phone number for
technical support will be provided on the meeting page at
www.virtualshareholdermeeting.com/ATXI2020. Technical support will
be available beginning at 9:45 a.m. Eastern Time on June 16, 2020
and will remain available until the meeting has ended.
Whether or not stockholders plan to attend the
virtual Annual Meeting, Avenue urges stockholders to select one of
the methods described in the proxy materials to vote and submit
their proxies in advance of the Annual Meeting.
About Avenue TherapeuticsAvenue
Therapeutics is a specialty pharmaceutical company whose mission is
to develop IV tramadol, a potential alternative that could reduce
the use of conventional opioids, for patients suffering from acute
pain in the U.S. Avenue is headquartered in New York City and was
founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more
information, visit www.avenuetx.com.
Forward-Looking StatementsThis
press release may contain “forward-looking statements” within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, each as amended. Such
statements include, but are not limited to, any statements relating
to our growth strategy and product development programs and any
other statements that are not historical facts. Forward-looking
statements are based on management’s current expectations and are
subject to risks and uncertainties that could negatively affect our
business, operating results, financial condition and stock value.
Factors that could cause actual results to differ materially from
those currently anticipated include: risks related to us obtaining
regulatory approval from the FDA for our product candidate, risks
relating to the COVID-19 outbreak and its potential impact on our
employees’ and consultants’ ability to complete work in a timely
manner, risks relating to our growth strategy; risks relating to
the results of research and development activities; risks relating
to the timing of starting and completing clinical trials; our
ability to obtain, perform under and maintain financing and
strategic agreements and relationships; uncertainties relating to
preclinical and clinical testing; our dependence on third-party
suppliers; our ability to attract, integrate and retain key
personnel; the early stage of products under development; our need
for substantial additional funds; government regulation; patent and
intellectual property matters; competition; as well as other risks
described in our SEC filings. We expressly disclaim any obligation
or undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in our expectations or any changes in events, conditions or
circumstances on which any such statement is based, except as
required by law.
Contacts: Jaclyn Jaffe and
William BegienAvenue Therapeutics, Inc. (781)
652-4500ir@avenuetx.com
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fortress Biotech (NASDAQ:FBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024